Abstract
Abstract
Background
This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of either tumor necrosis factor inhibitors (TNFi) or interleukin-6 inhibitors (IL-6i) in patients with elderly-onset rheumatoid arthritis (EORA).
Methods
Patients with rheumatoid arthritis (RA) enrolled in a Japanese multicenter observational registry between 2011 and 2020 were included. EORA was defined as RA with onset at 60 or over. To adjust confounding by indication for treatment with TNFi or IL-6i, a propensity score based on multiple baseline characteristics variables was used to compare the drug retention and causes for discontinuation between TNFi and IL-6i. Adjusted cumulative incidence of drug discontinuation for each reason was compared between the two groups using the Fine-Gray model.
Results
Among a total of 9,550 patients in the registry, 674 TNFi and 297 IL-6i initiators with EORA were identified. Age, the proportion of females, disease duration, and baseline disease activity at the time of TNFi or IL-6i initiation were similar between the two groups. After adjusting for differences in baseline characteristics between the two groups, overall drug discontinuation was significantly lower in the IL-6i as compared to the TNFi (HR = 0.71, 95%CI = 0.59–0.86, p < 0.001). The adjusted cumulative incidence of discontinuation due to lack of effectiveness was lower with the IL-6i (HR = 0.46, 95%CI = 0.33–0.63, p < 0.001) while those due to adverse events (HR = 0.82, 95%CI = 0.56–1.18, p = 0.28) or achievement of clinical remission (HR = 1.09, 95%CI = 0.62–1.91, p = 0.76) were similar between the two groups.
Conclusions
In EORA patients initiating a TNFi or IL-6i, significantly higher drug retention was observed with IL-6i. Discontinuation due to lack of effectiveness was significantly less frequent in IL-6i while discontinuations due to adverse event or achievement of clinical remission were similar between the two groups.
Funder
AbbVie
Asahi Kasei Pharma Corporation
Ayumi Pharmaceutical Co
Chugai Pharmaceutical
Eisai
Ono Pharmaceutical
Sanofi
Janssen Pharmaceuticals
information technology services company
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Koller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford). 2009;48(12):1575–80. https://doi.org/10.1093/rheumatology/kep291.
2. Mueller RB, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, von Kempis J. SCQM physicians: is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford). 2014;53(4):671–7. https://doi.org/10.1093/rheumatology/ket399.
3. Kato E, Sawada T, Tahara K, Hayashi H, Tago M, Mori H, Nishino J, Matsui T, Tohma S. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis. 2017;20(7):839–45. https://doi.org/10.1111/1756-185X.12998.
4. Deal CL, Meenan RF, Goldenberg DL, Anderson JJ, Sack B, Pastan RS, Cohen AS. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum. 1985;28(9):987–94. https://doi.org/10.1002/art.1780280905.
5. van der Heijde D. M, van riel PL, van Leeuwen MA, van 't Hof, M A, van Rijswijk MH, van de Putte, L B: Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective follow-up study of early rheumatoid arthritis. J Rheumatol. 1991;18(9):1285–9.